Results 141 to 150 of about 212,526 (280)

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

ImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia

BMC Infectious Diseases
Background X-linked agammaglobulinemia (XLA), also referred to as Bruton’s tyrosine kinase deficiency, is a rare genetic disorder that affects the immune system.
Bowen Dai, Shujuan Han, Yuanfang Shen, Zhi Li, Shouhang Chen, Zhuangzhuang Wang, Yan Yuan, Ruyu Zhang, Chenyu Wang, Jiaying Zheng, Qiujing Liang, Qingmei Wang, Yaodong Zhang, Xiaolong Zhang, Fang Wang, Yuefei Jin   +15 more
doaj   +1 more source

Profound Sinoatrial Arrest Associated with Ibrutinib

Case Reports in Oncological Medicine, 2017
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur, Aditya Saini, Kenneth A. Ellenbogen, Richard K. Shepard   +3 more
doaj   +1 more source

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity [PDF]

, 2020
Hyewon Cho, Eun Lee, Hye Ah Kwon, Seul Lee, Hui-Jeon Jeon, Ji Hoon Yu, Jae‐Ha Ryu, Raok Jeon   +7 more
openalex   +1 more source

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, Volume 101, Issue 5, Page 1025-1035, May 2026.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Frontiers in Immunology, 2021
C. I. Edvard Smith, Jennifer R. Brown, Rula Zain, Rula Zain   +3 more
doaj   +1 more source

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "

Iranian Journal of Allergy, Asthma and Immunology, 2004
X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the Bruton tyrosine kinase (Btk) gene. In order to identify the mutations in Btk gene in Iranian patients with antibody deficiency, 13 male patients with an XLA phenotype ...
"Asghar Aghamohammadi, Nima Parvaneh, Hirokazu Kanegana, Mostafa Moin, Ali Akbar Amirzargar, Abolhassan Farhoudi, Zahra Pourpak, Masoud Movahedi, Mohammad Gharagozlou, Nima Rezaei, Takeshi Futatani, Toshio Miyawaki "   +11 more
doaj  

Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors [PDF]

, 2019
Mengzhen Lai, Peiran Song, Dou Dou, Yanyan Diao, Linjiang Tong, Tao Zhang, Hua Xie, Honglin Li, Jian Ding   +8 more
openalex   +1 more source